Secondary myelofibrosis
Secondary myelofibrosis refers to a group of diseases caused by fibrosis of bone marrow hematopoietic tissue due to various different causes, which affects the hematopoietic function.
-
Site of disease:
marrow -
Infectious :
Not contagious -
Frequent population:
Middle-aged and elderly people -
Related symptoms:
Fatigue abdominal distension weight loss splenomegaly lymph node enlargement -
Concurrent disease:
Related Drugs
OJJAARA- momelotinib_tablet
Indication: OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Manufacturer:
GlaxoSmithKline LLC